摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(5-(4-propoxy-2-(trifluoromethyl)phenyl)pyrimidin-2-yl)methyl methanesulfonate | 1494718-09-0

中文名称
——
中文别名
——
英文名称
(5-(4-propoxy-2-(trifluoromethyl)phenyl)pyrimidin-2-yl)methyl methanesulfonate
英文别名
——
(5-(4-propoxy-2-(trifluoromethyl)phenyl)pyrimidin-2-yl)methyl methanesulfonate化学式
CAS
1494718-09-0
化学式
C16H17F3N2O4S
mdl
——
分子量
390.383
InChiKey
UCQHVZUBKPXECU-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.43
  • 重原子数:
    26.0
  • 可旋转键数:
    7.0
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.38
  • 拓扑面积:
    78.38
  • 氢给体数:
    0.0
  • 氢受体数:
    6.0

反应信息

  • 作为反应物:
    描述:
    2-(2,3-difluorophenyl)-5H-imidazo[4,5-d]pyridazine(5-(4-propoxy-2-(trifluoromethyl)phenyl)pyrimidin-2-yl)methyl methanesulfonatepotassium carbonate 作用下, 以 N,N-二甲基甲酰胺 为溶剂, 反应 1.0h, 以38 mg的产率得到2-(2,3-difluorophenyl)-5-((5-(4-propoxy-2-(trifluoromethyl)phenyl)pyrimidin-2-yl)methyl)-5H-imidazo[4,5-d]pyridazine
    参考文献:
    名称:
    Imidazopyridazine Hepatitis C Virus Polymerase Inhibitors. Structure–Activity Relationship Studies and the Discovery of a Novel, Traceless Prodrug Mechanism
    摘要:
    By reducing the basicity of the core heterocycle in a series of HCV NS5B inhibitors, the hERG liability was reduced. The SAR was then systematically explored in order to increase solubility and enable dose escalation while retaining potency. During this exploration, a facile decarboxylation was noted and was exploited as a novel prodnig mechanism. The synthesis and characterization of these prodrugs and their utilization in chronic toxicity studies are presented.
    DOI:
    10.1021/jm401337x
  • 作为产物:
    参考文献:
    名称:
    Imidazopyridazine Hepatitis C Virus Polymerase Inhibitors. Structure–Activity Relationship Studies and the Discovery of a Novel, Traceless Prodrug Mechanism
    摘要:
    By reducing the basicity of the core heterocycle in a series of HCV NS5B inhibitors, the hERG liability was reduced. The SAR was then systematically explored in order to increase solubility and enable dose escalation while retaining potency. During this exploration, a facile decarboxylation was noted and was exploited as a novel prodnig mechanism. The synthesis and characterization of these prodrugs and their utilization in chronic toxicity studies are presented.
    DOI:
    10.1021/jm401337x
点击查看最新优质反应信息